JP2014509653A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509653A5
JP2014509653A5 JP2014502821A JP2014502821A JP2014509653A5 JP 2014509653 A5 JP2014509653 A5 JP 2014509653A5 JP 2014502821 A JP2014502821 A JP 2014502821A JP 2014502821 A JP2014502821 A JP 2014502821A JP 2014509653 A5 JP2014509653 A5 JP 2014509653A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
treatment
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014502821A
Other languages
English (en)
Japanese (ja)
Other versions
JP6242331B2 (ja
JP2014509653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031361 external-priority patent/WO2012135571A1/en
Publication of JP2014509653A publication Critical patent/JP2014509653A/ja
Publication of JP2014509653A5 publication Critical patent/JP2014509653A5/ja
Application granted granted Critical
Publication of JP6242331B2 publication Critical patent/JP6242331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014502821A 2011-04-01 2012-03-30 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター Active JP6242331B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US61/470,849 2011-04-01
US201161559489P 2011-11-14 2011-11-14
US61/559,489 2011-11-14
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155625A Division JP6275784B2 (ja) 2011-04-01 2016-08-08 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター

Publications (3)

Publication Number Publication Date
JP2014509653A JP2014509653A (ja) 2014-04-21
JP2014509653A5 true JP2014509653A5 (enExample) 2015-04-09
JP6242331B2 JP6242331B2 (ja) 2017-12-06

Family

ID=46931927

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014502821A Active JP6242331B2 (ja) 2011-04-01 2012-03-30 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
JP2016155625A Active JP6275784B2 (ja) 2011-04-01 2016-08-08 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
JP2018001910A Withdrawn JP2018052987A (ja) 2011-04-01 2018-01-10 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016155625A Active JP6275784B2 (ja) 2011-04-01 2016-08-08 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
JP2018001910A Withdrawn JP2018052987A (ja) 2011-04-01 2018-01-10 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター

Country Status (29)

Country Link
US (7) US8710219B2 (enExample)
EP (2) EP3111938B1 (enExample)
JP (3) JP6242331B2 (enExample)
KR (2) KR20180108848A (enExample)
CN (2) CN103582483B (enExample)
AU (1) AU2012236367B2 (enExample)
BR (1) BR112013025340B1 (enExample)
CA (1) CA2830822C (enExample)
CL (1) CL2013002823A1 (enExample)
CY (2) CY1117785T1 (enExample)
DK (2) DK3111938T3 (enExample)
EA (1) EA022434B9 (enExample)
ES (2) ES2577982T3 (enExample)
HR (2) HRP20160545T1 (enExample)
HU (2) HUE028910T2 (enExample)
IL (2) IL228588A (enExample)
LT (1) LT3111938T (enExample)
ME (2) ME02451B (enExample)
MX (1) MX340577B (enExample)
PE (1) PE20141382A1 (enExample)
PL (2) PL3111938T3 (enExample)
PT (2) PT2694075T (enExample)
RS (2) RS54903B1 (enExample)
SG (2) SG10201602569RA (enExample)
SI (2) SI2694075T1 (enExample)
SM (2) SMT201900435T1 (enExample)
TW (1) TWI571469B (enExample)
WO (1) WO2012135571A1 (enExample)
ZA (2) ZA201307082B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
CA2830822C (en) * 2011-04-01 2018-10-02 Curis, Inc. A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
JP6051434B2 (ja) 2011-11-14 2016-12-27 イグニタ、インク. AXLおよびc−METキナーゼ阻害剤としてのウラシル誘導体
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
KR102015826B1 (ko) * 2015-04-21 2019-08-29 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도
US11142552B2 (en) * 2016-07-19 2021-10-12 National Institute Of Plant Genome Research Protein against fungal pathogens
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2018360845B2 (en) * 2017-11-06 2024-05-02 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
ES3014591T3 (en) 2018-09-11 2025-04-23 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
CN100503599C (zh) 2002-03-13 2009-06-24 詹森药业有限公司 作为组蛋白脱乙酰酶的新颖抑制剂的羰基氨基衍生物
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
KR20040090978A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
CA2514407C (en) 2003-01-29 2012-01-03 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US8227636B2 (en) * 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20080213399A1 (en) 2005-02-03 2008-09-04 Topotarget Uk Limited Combination Therapies Using Hdac Inhibitors
EP1885710B1 (en) 2005-05-18 2015-08-19 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
ES2396986T3 (es) 2006-01-19 2013-03-01 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
EP1979328B1 (en) 2006-01-19 2012-12-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007127175A2 (en) * 2006-04-26 2007-11-08 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス,インコーポレイテッド 亜鉛結合部分を含むキナゾリン系egfrインヒビター
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
RU2459811C2 (ru) 2006-10-28 2012-08-27 Метилджен Инк. Ингибиторы гистоновой деацетилазы
AU2007329352B2 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2114950B1 (en) * 2006-12-07 2016-03-09 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
EP2136809A4 (en) 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 PI3K/mTOR阻害剤
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
EP2405916B1 (en) 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
PH12012500709A1 (en) 2009-10-12 2012-10-29 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療
CA2830822C (en) * 2011-04-01 2018-10-02 Curis, Inc. A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
CN114796501A (zh) 2015-06-25 2022-07-29 免疫医疗公司 抗体与治疗剂的组合治疗癌症的方法
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Similar Documents

Publication Publication Date Title
JP2014509653A5 (enExample)
JP2014527042A5 (enExample)
JP2013522326A5 (enExample)
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2015501783A5 (enExample)
JP2012255026A5 (enExample)
JP2015536964A5 (enExample)
JP2015508103A5 (enExample)
JP2017537066A5 (enExample)
MX2014015158A (es) Derivados de piridinona y piridazinona.
JP2013525444A5 (enExample)
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
JP2014504256A5 (enExample)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2013526544A5 (enExample)
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2014502638A5 (enExample)
JP2014508804A5 (enExample)
JP2017514910A5 (enExample)
JP2014518544A5 (enExample)
RU2014117707A (ru) Способ лечения пролиферативного заболевания
JP2015509540A5 (enExample)
JP2018510138A5 (enExample)
JP2015516419A5 (enExample)
WO2013149148A3 (en) Dosage forms of halofuginone and methods of use